argenx SE | Results Presentation Deck | 21 slides

argenx · 2022-05
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

1
coverage by narrative range · generated from this deck JSON
Narrative range 21 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 21 slides 100% 21/21 slides 100% 21/21 slides · 87 hits
0/21 slides
19% 4/21 slides 23.8% 5/21 slides
0/21 slides
0/21 slides

Slide inventory

21
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
summarize
04
The slide uses a 2x2 grid layout to explain the pathophysiology of ITP, followed by a callout for the therapeutic solution.present_solution
05
Includes a patient photo and quote/persona context (Linda).diagnose_problem
06
The slide uses a timeline diagram to illustrate the 24-week trial structure.present_framework
07
The table displays patient counts and percentages for various categories including demographics, disease history, prior therapies, and baseline bleeding scores.analyze_data
08
The slide uses a line chart for longitudinal data and a bar chart for the primary endpoint outcome.analyze_data
09
The slide uses a line chart for longitudinal data and a stacked bar chart for categorical response rates.analyze_data
10
The chart includes error bars and patient counts at each time point.analyze_data
11
Forest plot showing 95% confidence intervals for treatment effect across multiple clinical variables.analyze_data
12
The table includes p-values and standard deviations for clinical metrics.analyze_data
13
The table compares safety metrics including AE frequency, severity, and specific categories of interest.analyze_data
14
summarize
15
The table shows a significant increase in operating loss driven by higher R&D and SG&A expenses, alongside a decrease in collaboration revenue.analyze_data
16
The slide uses a chevron process flow to represent strategic priorities.summarize
17
The slide uses a timeline-like graphic to connect the three pillars (Affordability, Predictability, Simplicity) and a stacked bar/arrow graphic to show coveragesummarize
18
summarize
19
Includes a visual of the 'My VYVGART Path' patient support material.illustrate_case
20
plan_implementation
21
The slide uses a timeline-like visual to show the expansion of indications for the drug VYVGART.summarize